Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into CareDx, Inc. for potential breaches of fiduciary duties and violations of federal securities laws [1][2]. Investigation Details - The investigation focuses on actions taken by CareDx insiders between April 30, 2020, and February 24, 2022, which involved issuing false and misleading statements about the company's compliance with healthcare laws and revenue growth [2]. - CareDx began disclosing issues on October 28, 2021, revealing that the company was under multiple government investigations and that its financial results were significantly lower than previously reported [2]. - By November 3, 2022, CareDx's share price had decreased by over 77.22% from its previous levels [2]. Shareholder Information - Current stockholders who have held CareDx stock since at least January 2021 are encouraged to contact Johnson Fistel to discuss their legal rights regarding the investigation [3].

Core Viewpoint - The proposed buyout of TaskUs, Inc. by its three largest shareholders, including Blackstone, is under investigation due to concerns about the fairness of the deal and potential conflicts of interest [1][4]. Company Overview - TaskUs is recognized as a leading provider of outsourced digital services and next-generation customer experience for innovative companies [2]. - The company has a positive outlook, with Wall Street analysts setting an average one-year stock price target of $18.50 per share, and a high target of $22 per share [2]. Buyout Details - On May 9, 2025, TaskUs announced its sale to a buyer group that already holds a majority of the company's voting power, with the buyout price set at $16.50 per share for public shareholders [3]. - The buyout is being pursued by Blackstone and co-founders Bryce Maddock and Jaspar Weir, who will continue their roles in the company post-acquisition [3][4]. Legal Investigation - Julie & Holleman LLP is investigating the buyout for potential legal claims, citing concerns over the deal's fairness and the low buyout price compared to the company's true value [1][4].

Core Viewpoint - Julie & Holleman LLP is investigating potential claims against Iovance Biotherapeutics, Inc. and its executives due to recent losses suffered by the company's stockholders [1][2]. Group 1: Legal Investigation - A complaint filed in federal court alleges that Iovance and its executives misled investors by exaggerating the company's financial prospects and downplaying risk factors affecting growth potential [2]. - The complaint specifically claims that the company concealed its inability to generate demand and was ill-equipped to capitalize on existing demand for its treatments through its network of approved treatment centers [2]. Group 2: Firm Background - Julie & Holleman LLP is a boutique law firm specializing in shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations [4]. - The firm's attorneys have a track record of securing hundreds of millions of dollars for aggrieved companies and their shareholders [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against ModivCare, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during a specified class period [1] Summary by Relevant Sections Class Action Allegations - The class action claims that ModivCare made misleading statements regarding its contracts' ability to stabilize cash flow, leading to significant stock price declines as the truth about the company's business emerged [2] - On September 16, 2024, ModivCare revised its 2024 Adjusted EBITDA guidance from a range of $185-$195 million to $170-$180 million, primarily due to pricing accommodations in the NEMT segment to retain key customer relationships [2] - Following this announcement, ModivCare's stock price dropped by $1.40, nearly 10%, from $14.12 per share on September 15, 2024, to $12.72 per share on September 16, 2024, with unusually high trading volume [2] Contact Information - Long-term stockholders of ModivCare who have information or questions regarding the claims can contact Bragar Eagel & Squire, P.C. via email or telephone, with no cost or obligation [3] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various complex litigations across state and federal courts [4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Kyverna Therapeutics, Inc. due to a class action complaint alleging that the company made false and misleading statements regarding its IPO and clinical data [1][2] Group 1: Legal Investigation - The investigation is focused on whether Kyverna's board of directors breached their fiduciary duties to the company [1] - A class action complaint was filed on December 9, 2024, related to the company's IPO conducted on February 8, 2024 [1] Group 2: Allegations of Misleading Information - The complaint states that Kyverna possessed adverse data related to one of its ongoing trials, which was not disclosed [2] - The undisclosed adverse data negatively impacted the company's lead product, making the trends and results in the offering documents misleading [2] - The company's discussion of risk factors was inadequate, failing to describe the risks associated with withholding clinical data [2] Group 3: Investor Impact - Investors suffered damages when the market learned the truth about Kyverna's misleading public statements [2]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against The Estee Lauder Companies Inc. regarding alleged breaches of fiduciary duties by its board of directors following a class action complaint filed on December 7, 2023 [1] Group 1: Allegations and Market Impact - The complaint alleges that Estee Lauder misled investors with unrealistic and materially false statements about market demand for its products and inventory levels [2] - These misleading statements concealed the company's market weaknesses until May 3, 2023, when Estee Lauder announced weaker-than-expected sales and profit, leading to a third consecutive cut in its fiscal year outlook [2] - Following this announcement, Estee Lauder's stock price fell from $245.22 per share on May 2, 2023, to $202.70 per share on May 3, 2023, reflecting a significant decline [2]

Core Viewpoint - Julie & Holleman LLP is investigating the acquisition of TaskUs, Inc. by a buyer group that includes the company's three largest shareholders, raising concerns about conflicts of interest and the fairness of the deal price [1][4]. Company Overview - TaskUs, Inc. is a leading provider of outsourced digital services and next-generation customer experience to innovative companies [2]. - Wall Street analysts have set one-year stock price targets for TaskUs, averaging $18.50 per share, with a high target of $22 per share [2]. Acquisition Details - On May 9, 2025, TaskUs announced its sale to a buyer group that already controls a majority of the company's voting power, with Blackstone, Maddock, and Weir offering to buy out public shareholders for $16.50 per share [3]. - The law firm Julie & Holleman believes the buyout price is significantly below the company's true value [4]. Legal Concerns - Julie & Holleman LLP is pursuing potential legal claims based on the apparent unfairness of the acquisition deal, highlighting conflicts of interest as key insiders remain with the company while public shareholders are cashed out at a low price [4].

SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether the board of directors of TaskUs, Inc. (NASDAQ: TASK) breached their fiduciary duties in connection with the proposed sale of the company to Blackstone, TaskUs Co-Founder and CEO Bryce Maddock, and Co-Founder and President Jaspar Weir (collectively, the “Buyer Group”). On May 9, 2025, TaskUs entered into a definitive agreement pursuant to which Buyer Group will acquire all outstanding shares ...

Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit w ...

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against NextEra Energy, Inc. (NYSE: NEE) on behalf of long-term stockholders following a class action complaint that was filed against NextEra with a Class Period from December 2, 2021, and February 1, 2023. Our investigation concerns whether the board of directors of NextEra have breached their fiduciary duties to the company. According to the Compla ...